Arthur D. Little Partners With European Space Agency to Deliver Multiple SatCom Studies
11.1.2021 17:31:00 EET | Business Wire | Press release
Arthur D. Little (ADL) today announced that it has been awarded multiple high impact projects by the European Space Agency (ESA) to help identify the most promising services for next generation satellite communication (SatCom) infrastructure. ADL will conduct a major consultation process with key members of the transport, energy, infrastructure and media industries, plus stakeholders in law enforcement and emergency services, to identify and assess potential applications and services that could be delivered via satellite in the next decade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005719/en/
Arthur D. Little has partnered with the European Space Agency to deliver multiple SatCom studies. (Photo: Business Wire)
ADL will be responsible for four studies in total. Three of the studies are part of the Advanced Research in Telecommunications Systems (ARTES) 4.0 Strategic Programme Line “Space Systems for Safety and Security” (4S), and are supported by the Italian Space Agency:
- Safety of Future Transport
- Safeguarding Essential Services
- Satellite Applications for Public Safety
As part of its ‘Open Consulting’ approach, ADL will conduct these studies with input from Distretto Tecnologico Aerospaziale (DTA).
The fourth study is an ARTES4.0 Business Applications Feasibility Study and is supported by the Norwegian Space Agency:
- Port of the Future
ADL will conduct this study in collaboration with Marlink and CLS.
With society and the economy dependent on telecommunications networks, the aim of 4S is to support the development of secure SatCom systems to both improve digital infrastructure resilience across Europe and the rest of the world, and provide innovative services and solutions. As terrestrial networks become increasingly vulnerable to disruption and attack, integrating next generation SatCom systems with the existing digital infrastructure can help make these networks more resilient and secure.
The Safety of Future Transport study will focus on how next generation SatCom solutions can increase safety and efficiency in the fast-evolving aviation, maritime and railway sectors, with potential applications relating to unmanned aircraft and ships, and automated traffic management systems. Safeguarding Essential Services will focus on how SatCom can help protect critical infrastructure such as energy utilities as well as public media. Satellite Applications for Public Safety will focus on how SatCom can supplement and support existing Public Protection and Disaster Relief (PPDR) networks used by first responders such as the police, fire brigade, health services and search & rescue.
The Port of the Future study will assess the technical feasibility and economic viability of new Earth observation and SatCom-based services for the port industry, focusing not only on operations of the port itself, but also on monitoring their environmental impact in terms of air and water quality.
Francesco Marsella, Managing Partner and Global S&O Practice Leader at ADL, comments: "SatCom has an increasingly vital role to play in protecting our society and making its infrastructure more secure and resilient. As terrestrial networks become more prone to failure, whether due to natural disaster or cyberattack, SatComs can support and maintain European telecoms systems. These studies will be key to developing existing satellite systems and identifying the services of the future.”
Lars Thurmann-Moe, Managing Partner, ADL Norway, comments: “It is not always appreciated quite how important the maritime sector remains, with the great majority of goods still transported by sea. SatCom is already central to modern maritime operations in terms of communication and navigation, but there is still so much more that can be done to improve these operations, and also reduce the industry’s environmental footprint – for instance, helping to quickly pinpoint oil spillages.”
Matteo Ainardi, Head of the Aerospace & Defense Competence Center at ADL, comments: "The satellite industry is today being disrupted by the introduction of new technologies such as large scale low earth orbit (LEO) constellations, reusable launchers and phased-array antennas. It is the right time to assess the evolving demand for SatCom solutions, and develop a next generation SatCom capability that can leverage these major technological breakthroughs to the benefit of the European society and economy. ADL is highly involved in the commercial space sector – as such, we are very pleased to be working with ESA on these studies, and look forward to applying our industry expertise to help define the SatCom-based services and applications of the future.”
To find out more about Arthur D. Little’s work in the space industry, please visit www.adlittle.com/en/industries/aerospace-defense
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005719/en/
Contact information
Cate Bonthuys
Catalyst Comms
+44 7746 546773
cate@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
